Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Condition(s):Generalized LipodystrophyLast Updated:March 12, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Generalized LipodystrophyLast Updated:March 12, 2024Active, not recruiting
Condition(s):Generalized LipodystrophyLast Updated:February 26, 2024Active, not recruiting
Condition(s):Lipodystrophy Acquired; Lipodystrophy CongenitalLast Updated:December 12, 2023Recruiting
Condition(s):Lipodystrophy; Diabetes; HyperlipidemiaLast Updated:February 26, 2024Recruiting
Condition(s):Hypoleptinemia; Generalized Lipodystrophy; Partial Lipodystrophy; Insulin ResistanceLast Updated:March 27, 2024Completed
Condition(s):Insulin Resistance – Type A; Insulin Resistance – Type B; Lipoatrophic Diabetes Mellitus; Insulin Resistance SyndromeLast Updated:June 3, 2021Unknown status
Condition(s):Insulin Resistance – Type A; Insulin Resistance – Type B; Lipoatrophic Diabetes Mellitus; Insulin Resistance SyndromeLast Updated:March 3, 2021Unknown status
Condition(s):LipodystrophyLast Updated:April 22, 2019Completed
Condition(s):Familial Partial LipodystrophyLast Updated:February 16, 2021Completed
Condition(s):LipodystrophyLast Updated:August 16, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.